International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva. (VULCA-NODE)
Sentinel Node Biopsy in Relapsed Vulvar Cancer. VULCA-NODE Study.
Acronym: VULCA-NODE Study Title: Sentinel Node Biopsy in Relapsed Vulvar Cancer Primary Objetive: To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting.
Secondary Objetives:
- To compare the utility of different tracers in the detection of SLN for recurrent disease and the injection pattern.
- To evaluate the surgical complications rate.
- To analyze the nodal status by ultrastaging .
- To assess the disease free and overall survival at 24 months from the first recurrence, as well as the dissemination pattern after the procedure.
Study Design: International prospective multicentre study
Inclusion Criteria:
- First local recurrent squamous cell carcinoma of the vulva (SCC).
- Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus.
- No distant or groin metastasis.
- To be able to understand the study and sign informed consent.
- Over 18 years old.
- To be able to undergo planned follow up.
Exclusion Criteria:
- Multifocal recurrent disease of the vulva.
- Previous bilateral IFL.
- Synchronous, non-curable second malignancy. Timing: 4 years
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28046
- La Paz University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- First local recurrent squamous cell carcinoma of the vulva (SCC).
- Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus.
- No distant or groin metastasis.
- To be able to understand the study and sign informed consent.
- Over 18 years old.
- To be able to undergo planned follow up.
Exclusion Criteria:
- Multifocal recurrent disease of the vulva.
- Previous bilateral IFL.
- Synchronous, non-curable second malignancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: First local recurrent vulvar carcinoma
|
All patients will undergo a local tumor radical excision and unilateral (if medial border > 1 cm from midline) or bilateral (medial border < or equal to 1 cm from midline) Sentinel Lymph Node procedure, followed by bilateral Inguinophemoral lymphadenectomy. .
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting.
Time Frame: From enrollment to the first 30 day after surgery
|
From enrollment to the first 30 day after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Genital Diseases, Female
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Vulvar Diseases
- Carcinoma
- Vulvar Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- HULP: PI-6605
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.